Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3129 - Real world data of osimertinib in patients with central nervous system (CNS) metastasis in ASTRIS Korean subset.


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Jin Hyoung Kang


Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292


J.H. Kang1, B.C. Cho2, D. Kim3, K. Park4, J. Lee5, S.S. Yoo6, S.Y. Lee7, C.H. Kim8, S.H. Jang9, Y. Kim10, H. Yoon11, S. Kim12

Author affiliations

  • 1 Medical Oncology, Seoul St. Mary's Hospital, of the Catholic University, 06591 - Seoul/KR
  • 2 Medical Oncology, Yonsei Cancer Center Yonsei University, 6273 - Seoul/KR
  • 3 101, Daehak-ro, Jongno-gu, Seoul National University Hospital, 03080 - seoul/KR
  • 4 Div. Of Heamatology/oncology, Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 5 Oncology, Seoul National University Bundang Hospital, 13620 - Gyeonggi-do/KR
  • 6 Department Of Internal Medicine, Kyungpook National University Hospital, 41404 - Daegyu/KR
  • 7 Department Of Internal Medicine, Korea University Guro Hospital, 08308 - seoul/KR
  • 8 Department Of Internal Medicine, Korea Cancer Center Hospital, 01812 - seoul/KR
  • 9 Department Of Internal Medicine,, Hallym University Sacred Heart Hospital, 14068 - Gyeonggi-do/KR
  • 10 Lung Cancer Clinic, Chonnam National University Hwasun Hospital, 58128 - Jeollanam-do/KR
  • 11 Department Of Internal Medicine, The Catholic University of Korea, Yeouido St. Mary's hospital, 07345 - seoul/KR
  • 12 Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul/KR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3129


More than 40% of non-small cell lung cancer (NSCLC) patients develop CNS metastasis in their lifetime. Clinical studies have shown superior efficacy of osimertinib in CNS compared to platinum chemotherapy. Treatment efficacy in patients with or without CNS metastasis were observed within the second interim analysis of ASTRIS (NCT02474355). Data cut-off (DCO) was 20 October 2017.


In ASTRIS, advanced NSCLC patients with locally confirmed T790M mutation, prior EGFR-TKI therapy were enrolled. Patients with stable CNS metastases were allowed. The primary endpoint was overall survival (OS); other endpoints included investigator-assessed response rate (RR), progression-free survival (PFS), time to treatment discontinuation (TTD) and safety. These endpoints were also analyzed according to presence of CNS metastasis.


In 466 Korean patients, CNS metastasis was evaluated in 310 patients and was present in 211 (68.1%) patients (CNS-met) and not present in 99 (31.9%) patients (CNS-no). 155 patients were not evaluated for CNS metastasis (CNS-ne). At DCO, 236 patients (50.6%) were ongoing and median duration of exposure was 11.2 (0–19) months. In patients evaluable for response, defined as at least one dose of osimertinib and one response assessment, RR was 71.0% (320/451; 95% CI, 66.5–75.1): Patients with (N = 211), without (N = 99), and not-evaluated CNS metastasis (N = 155) had RR of 68% (134/197), 79.6% (78/98), and 69.7% (108/155), respectively. Median PFS was 12.4 months (95% CI, 11.1-13.6); 10.8 months in CNS-met, 11.0 months in CNS-no, and 15.1 months in CNS-ne. Median TTD was 16.5 months (95% CI, 14.1-NC); 11.2 months in CNS-met, 14.7 months in CNS-no, and NC (95% CI, 15.5-NC) in CNS-ne. OS was not reached (data maturity: 19.7%). Serious adverse events (AE) regardless of causality were reported in 116 patients (24.9%) and AEs leading to death in 13 patients (2.8%). ILD/pneumonitis-like events were reported in 8 patients (1.7%), and QTc prolongation in 7 patients (1.5%).


In the ASTRIS Korean subset, patients with or without CNS metastasis had comparable efficacy outcomes. These data continue to support osimertinib’s clinical benefit on EGFRm T790M NSCLC patients with CNS metastasis.

Clinical trial identification


Legal entity responsible for the study




Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.